{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T18:02:35Z","timestamp":1771351355832,"version":"3.50.1"},"reference-count":259,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FEDER\u2014Fundo Europeu de Desenvolimento Regional"},{"name":"Portuguese funds","award":["UIDB\/4255\/2020"],"award-info":[{"award-number":["UIDB\/4255\/2020"]}]},{"name":"Portuguese funds","award":["RISE\u2014LA\/P\/0053\/2020"],"award-info":[{"award-number":["RISE\u2014LA\/P\/0053\/2020"]}]},{"name":"FCT","award":["IF\/00092\/2014\/CP1255\/CT0004"],"award-info":[{"award-number":["IF\/00092\/2014\/CP1255\/CT0004"]}]},{"name":"FCT","award":["PRR-09\/C06-834I07\/2024.P11721"],"award-info":[{"award-number":["PRR-09\/C06-834I07\/2024.P11721"]}]},{"name":"FCT","award":["2024.18026.PEX"],"award-info":[{"award-number":["2024.18026.PEX"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>HER2-low breast cancer has been recognized as a heterogenous group of tumors influenced by hormone receptor (HR) expression, giving rise to tumors with either a luminal-like phenotype or features resembling triple-negative breast cancer (TNBC). Despite the development of HER2-targeted therapies, several studies have demonstrated their limited efficacy in patients diagnosed with HER2-low breast cancer. However, recent research has led to the development of antibody-drug conjugates (ADCs), such as trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), with the latter showing promising results in treating these patients. Despite this breakthrough, the availability of a single effective therapy fails to account for tumor heterogeneity and may contribute to the emergence of therapy resistance, leaving HER2-low patients without treatment options. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at a post-transcriptional level and are capable of modulating key cellular processes. Recent studies have highlighted their potential as therapeutic targets, contributing to the advancement of personalized, patient-center therapies. In this context, the interplay between miRNAs and HER2-targeted therapies, particularly their modulation of common essential genes and signaling pathways, could reshape HER2-low therapy strategies to transform current practices aimed at improving the overall patient outcomes. Therefore, this review aims to elucidate the mechanisms underlying current HER2-targeted therapy and explore a potential crosstalk with miRNAs, ultimately serving as a guide for the development of personalized therapeutic strategies.<\/jats:p>","DOI":"10.3390\/cancers17223672","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:05:31Z","timestamp":1763463931000},"page":"3672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interplay Between MicroRNAs and Breast Cancer Therapies: Personalized Therapeutic Potential for HER2-Low Breast Cancer"],"prefix":"10.3390","volume":"17","author":[{"given":"Eduarda","family":"Carvalho","sequence":"first","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-6946","authenticated-orcid":false,"given":"Fernando","family":"Schmitt","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast Cancer: Pathogenesis and Treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/his.14786","article-title":"An Update on the Pathological Classification of Breast Cancer","volume":"82","author":"Rakha","year":"2022","journal-title":"Histopathology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.pathol.2016.10.012","article-title":"Molecular Classification of Breast Cancer: What the Pathologist Needs to Know","volume":"49","author":"Rakha","year":"2017","journal-title":"Pathology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5858\/arpa.2022-0070-RA","article-title":"Molecular Classification of Breast Cancer: Relevance and Challenges","volume":"147","author":"Zhang","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e38508","DOI":"10.1097\/MD.0000000000038508","article-title":"HER2\/PI3K\/AKT Pathway in HER2-Positive Breast Cancer: A Review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Cheng, X. (2024). A Comprehensive Review of HER2 in Cancer Biology and Therapeutics. Genes, 15.","DOI":"10.20944\/preprints202406.0515.v1"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5858\/2010-0454-RAR.1","article-title":"HER 2: Biology, Detection, and Clinical Implications","volume":"135","author":"Gutierrez","year":"2011","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kang, Y.J., Oh, S.J., Bae, S.Y., Kim, E.K., Lee, Y.J., Park, E.H., Jeong, J., Park, H.K., Suh, Y.J., and Kim, Y.S. (2023). Predictive Biological Factors for Late Survival in Patients with HER2-Positive Breast Cancer. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-38200-y"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.critrevonc.2023.103997","article-title":"A Review of HER2 Overexpression and Somatic Mutations in Cancers","volume":"186","author":"Galogre","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.breast.2021.07.019","article-title":"Dissecting the Biological Heterogeneity of HER2-Positive Breast Cancer","volume":"59","author":"Schettini","year":"2021","journal-title":"Breast"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1200\/JCO.22.02864","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","volume":"41","author":"Wolff","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1200\/JCO.19.02488","article-title":"HER2-Low Breast Cancer: Pathological and Clinical Landscape","volume":"38","author":"Tarantino","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Li, Y., Tsang, J.Y., Tam, F., Loong, T., and Tse, G.M. (2023). Comprehensive Characterization of HER2-Low Breast Cancers: Implications in Prognosis and Treatment. eBioMedicine, 91.","DOI":"10.1016\/j.ebiom.2023.104571"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-Low Breast Cancers: New Opportunities and Challenges","volume":"157","author":"Zhang","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"700","DOI":"10.4143\/crt.2023.1138","article-title":"HER2-Low Breast Cancer: Now and in the Future","volume":"56","author":"Kang","year":"2024","journal-title":"Cancer Res. Treat."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","article-title":"HER2-Low Breast Cancer: A New Subtype?","volume":"24","author":"Corti","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Agostinetto, E., Rediti, M., Fimereli, D., Debien, V., Piccart, M., Aftimos, P., Sotiriou, C., and de Azambuja, E. (2021). Her2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers, 13.","DOI":"10.3390\/cancers13112824"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/tbcr-23-48","article-title":"Challenges in HER2-Low Breast Cancer Identification, Detection, and Treatment","volume":"5","author":"Wu","year":"2024","journal-title":"Transl. Breast Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","article-title":"ESMO Expert Consensus Statements (ECS) on the Definition, Diagnosis, and Management of HER2-Low Breast Cancer","volume":"34","author":"Tarantino","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse Effects of Tyrosine Kinase Inhibitors in Cancer Therapy: Pathophysiology, Mechanisms and Clinical Management","volume":"8","author":"Sharma","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/1078-0432.CCR-20-2007","article-title":"Effects of HER Family-Targeting Tyrosine Kinase Inhibitors on Antibody-Dependent Cell-Mediated Cytotoxicity in HER2-Expressing Breast Cancer","volume":"27","author":"Collins","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103883","DOI":"10.1016\/j.critrevonc.2022.103883","article-title":"HER2-Low Breast Cancer: Novel Detections and Treatment Advances","volume":"181","author":"Wu","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1002\/jcp.27486","article-title":"An Overview of MicroRNAs: Biology, Functions, Therapeutics, and Analysis Methods","volume":"234","author":"Saliminejad","year":"2019","journal-title":"J. Cell Physiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1177\/0300985813502820","article-title":"MicroRNAs: History, Biogenesis, and Their Evolving Role in Animal Development and Disease","volume":"51","author":"Bhaskaran","year":"2014","journal-title":"Vet. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The Role of MicroRNAs in Human Cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Wong, J.S., and Cheah, Y.K. (2020). Potential MiRNAs for MiRNA-Based Therapeutics in Breast Cancer. Noncoding RNA, 6.","DOI":"10.3390\/ncrna6030029"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Syeda, Z.A., Langden, S.S.S., Munkhzul, C., Lee, M., and Song, S.J. (2020). Regulatory Mechanism of MicroRNA Expression in Cancer. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051723"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"R27","DOI":"10.1186\/bcr2257","article-title":"MicroRNA Signatures Predict Oestrogen Receptor, Progesterone Receptor and HER2\/Neureceptor Status in Breast Cancer","volume":"11","author":"Lowery","year":"2009","journal-title":"Breast Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Nair, M.G., Mavatkar, A.D., Naidu, C.M., VP, S., CE, A., Rajarajan, S., Sahoo, S., Mohan, G., Jaikumar, V.S., and Ramesh, R.S. (2024). Elucidating the Role of MicroRNA-18a in Propelling a Hybrid Epithelial\u2013Mesenchymal Phenotype and Driving Malignant Progression in ER-Negative Breast Cancer. Cells, 13.","DOI":"10.3390\/cells13100821"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.tig.2022.02.006","article-title":"Emerging Concepts of MiRNA Therapeutics: From Cells to Clinic","volume":"38","author":"Diener","year":"2022","journal-title":"Trends Genet."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Menon, A., Abd-Aziz, N., Khalid, K., Poh, C.L., and Naidu, R. (2022). MiRNA: A Promising Therapeutic Target in Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911502"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Scognamiglio, I., Di Martino, M.T., Campani, V., Virgilio, A., Galeone, A., Gull\u00e0, A., Gallo Cantafio, M.E., Misso, G., Tagliaferri, P., and Tassone, P. (2014). Transferrin-Conjugated SNALPs Encapsulating 2\u2019-O-Methylated MiR-34a for the Treatment of Multiple Myeloma. Biomed. Res. Int., 2014.","DOI":"10.1155\/2014\/217365"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3892\/ijmm.2021.4990","article-title":"MiR-29b Suppresses Proliferation and Induces Apoptosis of Hepatocellular Carcinoma Ascites H22 Cells via Regulating TGF-\u03921 and P53 Signaling Pathway","volume":"48","author":"Liu","year":"2021","journal-title":"Int. J. Mol. Med."},{"key":"ref_35","first-page":"25","article-title":"MiR-101-5p Acts as a Tumor Suppressor in HER2-Positive Breast Cancer Cells and Improves Targeted Therapy","volume":"14","author":"Normann","year":"2022","journal-title":"Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1007\/s11033-021-06996-5","article-title":"MiR-19a and MiR-421 Target PCA3 Long Non-Coding RNA and Restore PRUNE2 Tumor Suppressor Activity in Prostate Cancer","volume":"49","author":"Bozgeyik","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/onc.2009.445","article-title":"Regression of Murine Lung Tumors by the Let-7 MicroRNA","volume":"29","author":"Trang","year":"2010","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-020-00208-2","article-title":"Clinical, Pathological, and PAM50 Gene Expression Features of HER2-Low Breast Cancer","volume":"7","author":"Schettini","year":"2021","journal-title":"npj Breast Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12282-021-01303-3","article-title":"The Frequency of Low HER2 Expression in Breast Cancer and a Comparison of Prognosis between Patients with HER2-Low and HER2-Negative Breast Cancer by HR Status","volume":"29","author":"Horisawa","year":"2022","journal-title":"Breast Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101615","DOI":"10.1016\/j.esmoop.2023.101615","article-title":"Retrospective Study to Estimate the Prevalence and Describe the Clinicopathological Characteristics, Treatments Received, and Outcomes of HER2-Low Breast Cancer","volume":"8","author":"Viale","year":"2023","journal-title":"ESMO Open"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rey-Vargas, L., Bejarano-Rivera, L.M., Ballen, D.F., and Serrano-G\u00f3mez, S.J. (2024). Characterization of HER2-Low Breast Tumors among a Cohort of Colombian Women. Cancers, 16.","DOI":"10.3390\/cancers16183141"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"152326","DOI":"10.1016\/j.anndiagpath.2024.152326","article-title":"Landscape of HER2-Low Breast Cancer: Insights from a Six-Year Study on Prevalence and Clinicopathological Characteristics","volume":"72","author":"Khalil","year":"2024","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100087","DOI":"10.1016\/j.modpat.2022.100087","article-title":"HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes from Real-World Data of a Large Nationwide Cohort","volume":"36","author":"Andrinopoulou","year":"2023","journal-title":"Mod. Pathol."},{"key":"ref_44","first-page":"1","article-title":"Histological and Molecular Classification of Breast Cancer: What Do We Know?","volume":"30","author":"Otoni","year":"2020","journal-title":"Mastology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"7496","DOI":"10.1038\/s41467-023-43324-w","article-title":"Comprehensive Genomic Characterization of HER2-Low and HER2-0 Breast Cancer","volume":"14","author":"Tarantino","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-024-07495-4","article-title":"Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer","volume":"209","author":"Bansal","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-023-04076-9","article-title":"Analysis of Clinical Features, Genomic Landscapes and Survival Outcomes in HER2-Low Breast Cancer","volume":"21","author":"Jin","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tan, R.S.Y.C., Ong, W.S., Lee, K.H., Lim, A.H., Park, S., Park, Y.H., Lin, C.H., Lu, Y.S., Ono, M., and Ueno, T. (2022). HER2 Expression, Copy Number Variation and Survival Outcomes in HER2-Low Non-Metastatic Breast Cancer: An International Multicentre Cohort Study and TCGA-METABRIC Analysis. BMC Med., 20.","DOI":"10.1186\/s12916-022-02284-6"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Merlin, J.L., Husson, M., Sahki, N., Gilson, P., Massard, V., Harl\u00e9, A., and Leroux, A. (2023). Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS). Biomedicines, 11.","DOI":"10.3390\/biomedicines11123164"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/bit.28029","article-title":"Biogenesis and Mechanisms of MicroRNA-Mediated Gene Regulation","volume":"119","author":"Rani","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrg2843","article-title":"The Widespread Regulation of MicroRNA Biogenesis, Function and Decay","volume":"11","author":"Krol","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"O\u2019Brien, J., Hayder, H., Zayed, Y., and Peng, C. (2018). Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00402"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Varghese, L.N., Schwenke, D.O., and Katare, R. (2023). Role of Noncoding RNAs in Cardiac Ageing. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1142575"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrm3838","article-title":"Regulation of MicroRNA Biogenesis","volume":"15","author":"Ha","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/wrna.1680","article-title":"Biogenesis, Characterization, and Functions of Mirtrons","volume":"13","author":"Salim","year":"2022","journal-title":"Wiley Interdiscip. Rev. RNA"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1093\/nar\/gkx779","article-title":"Dicer-Independent Processing of Small RNA Duplexes: Mechanistic Insights and Applications","volume":"45","author":"Berkhout","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Sadakierska-Chudy, A. (2020). MicroRNAs: Diverse Mechanisms of Action and Their Potential Applications as Cancer Epi-Therapeutics. Biomolecules, 10.","DOI":"10.3390\/biom10091285"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e104569","DOI":"10.15252\/embj.2020104569","article-title":"Translation Is Required for MiRNA-dependent Decay of Endogenous Transcripts","volume":"40","author":"Biasini","year":"2021","journal-title":"EMBO J."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3390\/ijms14010480","article-title":"Recent Insights and Novel Bioinformatics Tools to Understand the Role of MicroRNAs Binding to 5\u2032 Untranslated Region","volume":"14","author":"Masotti","year":"2012","journal-title":"Int. J. Mol. Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"9667","DOI":"10.1073\/pnas.0703820104","article-title":"Target MRNAs Are Repressed as Efficiently by MicroRNA-Binding Sites in the 5\u2032 UTR as in the 3\u2032 UTR","volume":"104","author":"Lytle","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"10898","DOI":"10.1038\/s41467-024-55274-y","article-title":"NaP-TRAP Reveals the Regulatory Grammar in 5\u2032UTR-Mediated Translation Regulation during Zebrafish Development","volume":"15","author":"Strayer","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1159\/000362952","article-title":"Transcriptional Regulation of Gene Expression by MicroRNAs as Endogenous Decoys of Transcription Factors","volume":"33","author":"Cui","year":"2014","journal-title":"Cell Physiol. Biochem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"114372","DOI":"10.1016\/j.yexcr.2024.114372","article-title":"Paradigm Shift: MicroRNAs Interact with Target Gene Promoters to Cause Transcriptional Gene Activation or Silencing","volume":"444","author":"Sarkar","year":"2025","journal-title":"Exp. Cell Res."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Bai, Y., Pan, B., Zhan, X., Silver, H., and Li, J. (2021). Microrna 195-5p Targets Foxo3 Promoter Region to Regulate Its Expression in Granulosa Cells. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136721"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jie, M., Feng, T., Huang, W., Zhang, M., Feng, Y., Jiang, H., and Wen, Z. (2021). Subcellular Localization of MiRNAs and Implications in Cellular Homeostasis. Genes, 12.","DOI":"10.3390\/genes12060856"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Wu, T., Song, H., Xie, D., Hua, K., Hu, J., Deng, Y., Ji, C., and Fang, L. (2020). Mir-30b-5p Promotes Proliferation, Migration, and Invasion of Breast Cancer Cells via Targeting ASPP2. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/7907269"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3892\/or.2015.3713","article-title":"MiRNA 542 3p Downregulation Promotes Trastuzumab Resistance in Breast Cancer Cells via AKT Activation","volume":"33","author":"Ma","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"37269","DOI":"10.18632\/oncotarget.5495","article-title":"MicroRNA-21 Links Epithelial-to-Mesenchymal Transition and Inflammatory Signals to Confer Resistance to Neoadjuvant Trastuzumab and Chemotherapy in HER2-Positive Breast Cancer Patients","volume":"6","author":"Bottai","year":"2015","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Ortega, M.A., Fraile-Mart\u00ednez, O., Guijarro, L.G., Casanova, C., Coca, S., \u00c1lvarez-Mon, M., Buj\u00e1n, J., Garc\u00eda-Honduvilla, N., and As\u00fansolo, \u00c1. (2020). The Regulatory Role of Mitochondrial MicroRNAs (MitomiRs) in Breast Cancer: Translational Implications Present and Future. Cancers, 12.","DOI":"10.3390\/cancers12092443"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.mito.2022.08.002","article-title":"Mitochondrial MiRNAs (MitomiRs): Their Potential Roles in Breast and Other Cancers","volume":"66","author":"Erturk","year":"2022","journal-title":"Mitochondrion"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cmet.2019.07.011","article-title":"Extracellular MiRNAs: From Biomarkers to Mediators of Physiology and Disease","volume":"30","author":"Mori","year":"2019","journal-title":"Cell Metab."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Pozniak, T., Shcharbin, D., and Bryszewska, M. (2022). Circulating MicroRNAs in Medicine. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23073996"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-023-01741-x","article-title":"Recent Advances of Small Extracellular Vesicle Biomarkers in Breast Cancer Diagnosis and Prognosis","volume":"22","author":"Lee","year":"2023","journal-title":"Mol. Cancer"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12964-023-01259-1","article-title":"Acute Myeloid Leukemia-Derived Exosomes Deliver MiR-24-3p to Hinder the T-Cell Immune Response through DENN\/MADD Targeting in the NF-\u039aB Signaling Pathways","volume":"21","author":"Otmani","year":"2023","journal-title":"Cell Commun. Signal"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-020-00991-2","article-title":"Tumor-Derived Exosomal MiR-934 Induces Macrophage M2 Polarization to Promote Liver Metastasis of Colorectal Cancer","volume":"13","author":"Zhao","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6827","DOI":"10.1007\/s11033-021-07040-2","article-title":"Spectrum of MicroRNAs and Their Target Genes in Cancer: Intervention in Diagnosis and Therapy","volume":"49","author":"Dayakar","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.molmed.2014.06.005","article-title":"MicroRNAs in Cancer: Biomarkers, Functions and Therapy","volume":"20","author":"Hayes","year":"2014","journal-title":"Trends Mol. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The Hallmarks of Cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of Cancer: The next Generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Ciccarone, F., and Ciriolo, M.R. (2023). Editorial: Hallmark of Cancer: Sustained Proliferative Signalling. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1328827"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13046-025-03391-x","article-title":"MicroRNA in Cancer Therapy: Breakthroughs and Challenges in Early Clinical Applications","volume":"44","author":"Tagliaferri","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Park, S.E., Kim, W., Hong, J.Y., Kang, D., Park, S., Suh, J., You, D., Park, Y.Y., Suh, N., and Hwang, J.J. (2022). MiR-96-5p Targets PTEN to Mediate Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-07468-x"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.3892\/etm.2021.10452","article-title":"MicroRNA 449a Inhibits Cell Proliferation and Migration by Regulating Mutant P53 in MDA MB 468 Cells","volume":"22","author":"Huang","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as Anticancer Mechanism: Function and Dysfunction of Its Modulators and Targeted Therapeutic Strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/jcb.30173","article-title":"Review of Cancer Cell Resistance Mechanisms to Apoptosis and Actual Targeted Therapies","volume":"123","author":"Kulbay","year":"2022","journal-title":"J. Cell Biochem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.semcancer.2014.01.006","article-title":"Tumor Viruses and Replicative Immortality\u2014Avoiding the Telomere Hurdle","volume":"26","author":"Chen","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Bailey, S.M. (2023). Editorial: Hallmark of Cancer: Replicative Immortality. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1204094"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor Angiogenesis: Causes, Consequences, Challenges and Opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol. Life Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","article-title":"A Concise Review of VEGF, PDGF, FGF, Notch, Angiopoietin, and HGF Signalling in Tumor Angiogenesis with a Focus on Alternative Approaches and Future Directions","volume":"221","author":"Vimalraj","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Shaw, P., Dwivedi, S.K.D., Bhattacharya, R., Mukherjee, P., and Rao, G. (2024). VEGF Signaling: Role in Angiogenesis and Beyond. Biochim. Biophys. Acta Rev. Cancer, 1879.","DOI":"10.1016\/j.bbcan.2024.189079"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00404-021-06198-1","article-title":"The Role of E-Cadherin Expression in Primary Site of Breast Cancer","volume":"305","author":"Karsten","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-025-02148-4","article-title":"Invasion and Metastasis in Cancer: Molecular Insights and Therapeutic Targets","volume":"10","author":"Li","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s13046-018-0911-3","article-title":"Melanoma Cell-Secreted Exosomal MiR-155-5p Induce Proangiogenic Switch of Cancer-Associated Fibroblasts via SOCS1\/JAK2\/STAT3 Signaling Pathway","volume":"37","author":"Zhou","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/cas.15726","article-title":"Omental Cancer-Associated Fibroblast-Derived Exosomes with Low MicroRNA-29c-3p Promote Ovarian Cancer Peritoneal Metastasis","volume":"114","author":"Han","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.7150\/thno.62378","article-title":"Metabolic Reprogramming of Cancer-Associated Fibroblasts and Its Effect on Cancer Cell Reprogramming","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Xuekai, L., Yan, S., Jian, C., Yifei, S., Xinyue, W., Wenyuan, Z., Shuwen, H., and Xi, Y. (2024). Advances in Reprogramming of Energy Metabolism in Tumor T Cells. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1347181"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3128933","DOI":"10.1155\/2022\/3128933","article-title":"Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis","volume":"2022","author":"Bi","year":"2022","journal-title":"J. Immunol. Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","article-title":"Immune Evasion in Cancer: Mechanisms and Cutting-Edge Therapeutic Approaches","volume":"10","author":"Tufail","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1038\/emboj.2012.45","article-title":"A Novel MiR-155\/MiR-143 Cascade Controls Glycolysis by Regulating Hexokinase 2 in Breast Cancer Cells","volume":"31","author":"Jiang","year":"2012","journal-title":"EMBO J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"107990","DOI":"10.1016\/j.intimp.2021.107990","article-title":"Pancreatic Cancer Cell-Derived MicroRNA-155-5p-Containing Extracellular Vesicles Promote Immune Evasion by Triggering EHF-Dependent Activation of Akt\/NF-\u039aB Signaling Pathway","volume":"100","author":"Wang","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Entezari, M., Soltani, B.M., and Sadeghizadeh, M. (2024). MicroRNA-203a Inhibits Breast Cancer Progression through the PI3K\/Akt and Wnt Pathways. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-52940-5"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"110636","DOI":"10.1016\/j.cellsig.2023.110636","article-title":"MiR-199a-3p Promotes Gastric Cancer Progression by Promoting Its Stemness Potential via DDR2 Mediation","volume":"106","author":"Ren","year":"2023","journal-title":"Cell Signal"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/1759-7714.15427","article-title":"MiR-30c-5p Inhibits Esophageal Squamous Cell Carcinoma Progression by Repressing the PI3K\/AKT Signaling Pathway","volume":"15","author":"Shi","year":"2024","journal-title":"Thorac. Cancer"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41419-023-05761-9","article-title":"MiR-122-5p Regulates the Mevalonate Pathway by Targeting P53 in Non-Small Cell Lung Cancer","volume":"14","author":"Zheng","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4784500","DOI":"10.1155\/2023\/4784500","article-title":"MiR-19-3p Targets PTEN to Regulate Cervical Cancer Cell Proliferation, Invasion, and Autophagy","volume":"2023","author":"Wang","year":"2023","journal-title":"Genet. Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"32707","DOI":"10.18632\/oncotarget.9017","article-title":"Extracellular MiR-1246 Promotes Lung Cancer Cell Proliferation and Enhances Radioresistance by Directly Targeting DR5","volume":"7","author":"Yuan","year":"2016","journal-title":"Oncotarget"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.2147\/OTT.S299234","article-title":"Mir-140-3p Impedes Gastric Cancer Progression and Metastasis by Regulating Bcl2\/Becn1-Mediated Autophagy","volume":"14","author":"Chen","year":"2021","journal-title":"Onco Targets Ther."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Liang, Y., Shi, C., Wang, Y., Fan, B., Song, W., and Shen, R. (2024). MiR-363-3p Induces Tamoxifen Resistance in Breast Cancer Cells through PTEN Modulation. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-83938-8"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s13105-015-0380-5","article-title":"Sen. MicroRNA-21 Controls HTERT via PTEN in Human Colorectal Cancer Cell Proliferation","volume":"71","author":"Yang","year":"2015","journal-title":"J. Physiol. Biochem."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ohira, T., Naohiro, S., Nakayama, Y., Osaki, M., Okada, F., Oshimura, M., and Kugoh, H. (2015). MiR-19b Regulates HTERT MRNA Expression through Targeting PITX1 MRNA in Melanoma Cells. Sci. Rep., 5.","DOI":"10.1038\/srep08201"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e189503","DOI":"10.1172\/jci.insight.189503","article-title":"MicroRNA-6084 Orchestrates Angiogenesis and Liver Metastasis in Colorectal Cancer via Extracellular Vesicles","volume":"10","author":"Zhang","year":"2025","journal-title":"JCI Insight"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41419-022-05420-5","article-title":"Cancer-Derived Exosomal MiR-197-3p Confers Angiogenesis via Targeting TIMP2\/3 in Lung Adenocarcinoma Metastasis","volume":"13","author":"Chang","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"7346460","DOI":"10.1155\/2022\/7346460","article-title":"Long Noncoding RNA MMP2-AS1 Contributes to Progression of Renal Cell Carcinoma by Modulating MiR-34c-5p\/MMP2 Axis","volume":"2022","author":"Fan","year":"2022","journal-title":"J. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Leoni, I., Galvani, G., Monti, E., Vianello, C., Valenti, F., Pincigher, L., Grolla, A.A., Moro, M., Coada, C.A., and Perrone, A. (2025). MiR-22\/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202503.0663.v1"},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Xu, D., Liu, B., and Wang, L. (2025). MiR-365-3p Inhibits Lung Cancer Proliferation and Migration via CPT1A-Mediated Fatty Acid Oxidation. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-91665-x"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/0008-5472.CAN-12-4318","article-title":"MiR-124 Inhibits STAT3 Signaling to Enhance T Cell-Mediated Immune Clearance of Glioma","volume":"73","author":"Wei","year":"2013","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9560","DOI":"10.1111\/jcmm.15367","article-title":"Endoplasmic Reticulum Stress-induced Exosomal MiR-27a-3p Promotes Immune Escape in Breast Cancer via Regulating PD-L1 Expression in Macrophages","volume":"24","author":"Yao","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.4161\/cc.20598","article-title":"MiR-145 Inhibits Tumor Angiogenesis and Growth by N-RAS and VEGF","volume":"11","author":"Zou","year":"2012","journal-title":"Cell Cycle"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1038\/s41467-021-22641-y","article-title":"MicroRNA-146a Limits Tumorigenic Inflammation in Colorectal Cancer","volume":"12","author":"Garo","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/0008-5472.CAN-12-0103","article-title":"MiR-96 Downregulates REV1 and RAD51 to Promote Cellular Sensitivity to Cisplatin and PARP Inhibition","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Yan, D., Ng, W.L., Zhang, X., Wang, P., Zhang, Z., Mo, Y.Y., Mao, H., Hao, C., Olson, J.J., and Curran, W.J. (2010). Targeting DNA-PKcs and ATM with MiR-101 Sensitizes Tumors to Radiation. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0011397"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1541-7786.MCR-18-0831","article-title":"MiRNA-148a-3p Regulates Immunosuppression in DNA Mismatch Repair-Deficient Colorectal Cancer by Targeting PD-L1","volume":"17","author":"Ashizawa","year":"2019","journal-title":"Mol. Cancer Res."},{"key":"ref_123","first-page":"265","article-title":"MicroRNA Significance in Cancer: An Updated Review on Diagnostic, Prognostic, and Therapeutic Perspectives","volume":"35","author":"Singh","year":"2024","journal-title":"Ejifcc"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/1535370217750088","article-title":"Biomarker Definitions and Their Applications","volume":"243","author":"Califf","year":"2018","journal-title":"Exp. Biol. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e12147","DOI":"10.7717\/peerj.12147","article-title":"Exosomal Hsa-MiR-21-5p Is a Biomarker for Breast Cancer Diagnosis","volume":"9","author":"Liu","year":"2021","journal-title":"PeerJ"},{"key":"ref_126","first-page":"14759","article-title":"Serum MiR-21 Level: A Potential Diagnostic and Prognostic Biomarker for Non-Small Cell Lung Cancer","volume":"8","author":"Zhao","year":"2015","journal-title":"Int. J. Clin. Exp. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1093\/jnci\/djt101","article-title":"Serum MiR-21 as a Diagnostic and Prognostic Biomarker in Colorectal Cancer","volume":"105","author":"Toiyama","year":"2013","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"56389","DOI":"10.18632\/oncotarget.16916","article-title":"Urine MiR-21-5p as a Potential Non-Invasive Biomarker for Gastric Cancer","volume":"8","author":"Kao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13014-023-02316-2","article-title":"Circulating MiR-21 as a Prognostic Biomarker in HCC Treated by CT-Guided High-Dose Rate Brachytherapy","volume":"18","author":"Stechele","year":"2023","journal-title":"Radiat. Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.12669\/pjms.35.5.331","article-title":"Circulating MiR-21 as a Prognostic and Predictive Biomarker in Oral Squamous Cell Carcinoma","volume":"35","author":"Mahmood","year":"2019","journal-title":"Pak. J. Med. Sci."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/jrr\/rrad043","article-title":"The Role of MiR-21 as a Predictive Biomarker and a Potential Target to Improve the Effects of Chemoradiotherapy against Head and Neck Squamous Cell Carcinoma","volume":"64","author":"Ishinaga","year":"2023","journal-title":"J. Radiat. Res."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Yang, G., Lu, Z., Meng, F., Wan, Y., Zhang, L., Xu, Q., and Wang, Z. (2022). Circulating MiR-141 as a Potential Biomarker for Diagnosis, Prognosis and Therapeutic Targets in Gallbladder Cancer. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-13430-8"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12943-019-0959-5","article-title":"Hypoxic BMSC-Derived Exosomal MiRNAs Promote Metastasis of Lung Cancer Cells via STAT3-Induced EMT","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.lungcan.2013.11.005","article-title":"Positive Prognostic Impact of MiR-210 in Non-Small Cell Lung Cancer","volume":"83","author":"Eilertsen","year":"2014","journal-title":"Lung Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1476-4598-13-142","article-title":"Evaluation of MicroRNA-10b Prognostic Significance in a Prospective Cohort of Breast Cancer Patients","volume":"13","author":"Parrella","year":"2014","journal-title":"Mol. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.3748\/wjg.v20.i22.6906","article-title":"Reduced Expression of Circulating MicroRNA-218 in Gastric Cancer and Correlation with Tumor Invasion and Prognosis","volume":"20","author":"Xin","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_137","first-page":"1","article-title":"MiR-218 Tissue Expression Level Is Associated with Aggressive Progression of Gastric Cancer","volume":"15","author":"Wang","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/gcc.22146","article-title":"Low Expression of MicroRNA-126 Is Associated with Poor Prognosis in Colorectal Cancer","volume":"53","author":"Liu","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"CLO25-090","DOI":"10.6004\/jnccn.2024.7226","article-title":"CLO25-090: MiR-31 as a Predictive Biomarker of Cetuximab Efficacy in Metastatic Colorectal Cancer Patients","volume":"23","author":"Thugu","year":"2025","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Caram\u00e9s, C., Cristobal, I., Moreno, V., Mar\u00edn, J.P., Gonz\u00e1lez-Alonso, P., Torrej\u00f3n, B., Minguez, P., Leon, A., Mart\u00edn, J.I., and Hern\u00e1ndez, R. (2016). MicroRNA-31 Emerges as a Predictive Biomarker of Pathological Response and Outcome in Locally Advanced Rectal Cancer. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17060878"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Wang, H., Tan, G., Dong, L., Cheng, L., Li, K., Wang, Z., and Luo, H. (2012). Circulating MiR-125b as a Marker Predicting Chemoresistance in Breast Cancer. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0034210"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1097\/MS9.0000000000001061","article-title":"Circulating MiR-221\/222 Expression as MicroRNA Biomarker Predicting Tamoxifen Treatment Outcome: A Case\u2013Control Study","volume":"85","author":"Patellongi","year":"2023","journal-title":"Ann. Med. Surg."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-017-0600-4","article-title":"Intra-Tumor Heterogeneity from a Cancer Stem Cell Perspective","volume":"16","author":"Prasetyanti","year":"2017","journal-title":"Mol. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1158\/1940-6207.CAPR-23-0156","article-title":"Differences in Serum MiRNA Profiles by Race, Ethnicity, & Socioeconomic Status: Implications for Developing an Equitable Ovarian Cancer Screening Test","volume":"17","author":"Alimena","year":"2024","journal-title":"Cancer Prev. Res."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Chen, B., Xia, Z., Deng, Y.N., Yang, Y., Zhang, P., Zhu, H., Xu, N., and Liang, S. (2019). Emerging MicroRNA Biomarkers for Colorectal Cancer Diagnosis and Prognosis. Open Biol., 9.","DOI":"10.1098\/rsob.180212"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.molcel.2015.04.005","article-title":"The Technology and Biology of Single-Cell RNA Sequencing","volume":"58","author":"Kolodziejczyk","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Proietto, M., Crippa, M., Damiani, C., Pasquale, V., Sacco, E., Vanoni, M., and Gilardi, M. (2023). Tumor Heterogeneity: Preclinical Models, Emerging Technologies, and Future Applications. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1164535"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41418-020-00730-7","article-title":"Single-Cell RNA Sequencing Reveals Intratumoral Heterogeneity in Primary Uveal Melanomas and Identifies HES6 as a Driver of the Metastatic Disease","volume":"28","author":"Pandiani","year":"2021","journal-title":"Cell Death Differ."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour Heterogeneity and Resistance to Cancer Therapies","volume":"15","author":"Shaw","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-023-01494-6","article-title":"Advances in Single-Cell RNA Sequencing and Its Applications in Cancer Research","volume":"16","author":"Huang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/2211738507666190122111224","article-title":"Drug Combinations in Breast Cancer Therapy","volume":"7","author":"Fisusi","year":"2019","journal-title":"Pharm. Nanotechnol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.soc.2019.08.004","article-title":"Precision Medicine and Targeted Therapies in Breast Cancer","volume":"29","author":"Greenwalt","year":"2020","journal-title":"Surg. Oncol. Clin. N. Am."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Guidi, L., Pellizzari, G., Tarantino, P., Valenza, C., and Curigliano, G. (2023). Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges. Cancers, 15.","DOI":"10.3390\/cancers15041130"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor Tyrosine Kinase Inhibitors in Cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.medidd.2024.100195","article-title":"Recent Developments in Receptor Tyrosine Kinase Inhibitors: A Promising Mainstay in Targeted Cancer Therapy","volume":"23","author":"Kumar","year":"2024","journal-title":"Med. Drug Discov."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3892\/etm.2021.11037","article-title":"Tyrosine Kinase Inhibitors in Breast Cancer","volume":"23","author":"Iancu","year":"2021","journal-title":"Exp. Ther. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"155607","DOI":"10.1016\/j.prp.2024.155607","article-title":"A Review on Tyrosine Kinase Inhibitors for Targeted Breast Cancer Therapy","volume":"263","author":"Sankarapandian","year":"2024","journal-title":"Pathol. Res. Pract."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of Small Molecule Protein Kinase Inhibitors Based upon the Structures of Their Drug-Enzyme Complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Voigtlaender, M., Schneider-Merck, T., and Trepel, M. (2018). Lapatinib. Small Molecules in Oncology, Springer. Recent Results in Cancer Research, Volume 211.","DOI":"10.1007\/978-3-319-91442-8_2"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"873","DOI":"10.20517\/cdr.2022.48","article-title":"Mechanisms of Neratinib Resistance in HER2-Mutant Metastatic Breast Cancer","volume":"5","author":"Eli","year":"2022","journal-title":"Cancer Drug Resist."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s40265-020-01340-w","article-title":"Tucatinib: First Approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated with \u2265 2 HER2-Directed Regimens: Phase III NALA Trial","volume":"38","author":"Saura","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1470-2045(20)30702-6","article-title":"Pyrotinib plus Capecitabine versus Lapatinib plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer (PHOEBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 Trial","volume":"22","author":"Xu","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"101807","DOI":"10.1016\/j.xcrm.2024.101807","article-title":"Preclinical Study and Phase 2 Trial of Neoadjuvant Pyrotinib Combined with Chemotherapy in Luminal\/HER2-Low Breast Cancer: PILHLE-001 Study","volume":"5","author":"Gong","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Maadi, H., Soheilifar, M.H., Choi, W.S., Moshtaghian, A., and Wang, Z. (2021). Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma. Cancers, 13.","DOI":"10.3390\/cancers13143540"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000346837","article-title":"HER2 Dimerization Inhibitor Pertuzumab\u2014Mode of Action and Clinical Data in Breast Cancer","volume":"8","author":"Harbeck","year":"2013","journal-title":"Breast Care"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"103915","DOI":"10.1016\/j.critrevonc.2023.103915","article-title":"Monoclonal Antibodies in Breast Cancer: A Critical Appraisal","volume":"183","author":"Behl","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Vu, T., and Claret, F.X. (2012). Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer. Front. Oncol., 2.","DOI":"10.3389\/fonc.2012.00062"},{"key":"ref_170","doi-asserted-by":"crossref","unstructured":"Vo, T.H., EL-Sherbieny Abdelaal, E., Jordan, E., O\u2019Donovan, O., McNeela, E.A., Mehta, J.P., and Rani, S. (2023). MiRNAs as Biomarkers of Therapeutic Response to HER2-Targeted Treatment in Breast Cancer: A Systematic Review. Biochem. Biophys. Rep., 37.","DOI":"10.1016\/j.bbrep.2023.101588"},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Zhu, K., Yang, X., Tai, H., Zhong, X., Luo, T., and Zheng, H. (2024). HER2-Targeted Therapies in Cancer: A Systematic Review. Biomark. Res., 12.","DOI":"10.1186\/s40364-024-00565-1"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1053\/j.seminoncol.2014.07.002","article-title":"Therapeutic Antibodies in Breast Cancer","volume":"41","author":"Scaltriti","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(24)00581-3","article-title":"De-Escalated Neoadjuvant Weekly Nab-Paclitaxel with Trastuzumab and Pertuzumab versus Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab in Patients with HER2-Positive Early Breast Cancer (HELEN-006): A Multicentre, Randomised, Phase 3 Trial","volume":"26","author":"Chen","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12957-024-03365-x","article-title":"Neoadjuvant Pertuzumab plus Trastuzumab in Combination with Chemotherapy for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer: A Real-World Retrospective Single-Institutional Study in China","volume":"22","author":"Peng","year":"2024","journal-title":"World J. Surg. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1007\/s12094-024-03440-5","article-title":"Real-World Experience with Pertuzumab and Trastuzumab Combined with Chemotherapy in Neoadjuvant Treatment for Patients with Early-Stage HER2-Positive Breast Cancer: The NEOPERSUR Study","volume":"26","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1038\/s41416-024-02665-z","article-title":"Neratinib Could Be Effective as Monotherapy or in Combination with Trastuzumab in HER2-Low Breast Cancer Cells and Organoid Models","volume":"130","author":"Arshad","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_177","doi-asserted-by":"crossref","unstructured":"Mark, C., Lee, J.S., Cui, X., and Yuan, Y. (2023). Antibody\u2013Drug Conjugates in Breast Cancer: Current Status and Future Directions. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813726"},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Fan, P., and Xu, K. (2023). Antibody-Drug Conjugates in Breast Cancer: Marching from HER2-Overexpression into HER2-Low. Biochim. Biophys. Acta Rev. Cancer, 1878.","DOI":"10.1016\/j.bbcan.2022.188849"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","article-title":"Trastuzumab Deruxtecan in Breast Cancer","volume":"198","author":"Pandiella","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab Emtansine: Mechanisms of Action and Drug Resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Eng. J. Med."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results from DESTINY-Breast03, a Randomised, Open-Label, Phase 3 Trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer: Long-Term Survival Analysis of the DESTINY-Breast03 Trial","volume":"30","author":"Hurvitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.12.012","article-title":"Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen Receptor Degraders (SERDs) in Cancer Treatment","volume":"186","author":"Patel","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/andr.12197","article-title":"Tamoxifen in Men: A Review of Adverse Events","volume":"4","author":"Wibowo","year":"2016","journal-title":"Andrology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"180","DOI":"10.3892\/mmr.2024.13304","article-title":"Crosstalk of Methylation and Tamoxifen in Breast Cancer","volume":"30","author":"Shen","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Generali, D., Berardi, R., Caruso, M., Cazzaniga, M., Garrone, O., Minchella, I., Paris, I., Pinto, C., and De Placido, S. (2023). Aromatase Inhibitors: The Journey from the State of the Art to Clinical Open Questions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1249160"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"e2000081","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase Inhibitors: Role in Postmenopausal Breast Cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch. Pharm."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e137571","DOI":"10.1172\/jci.insight.137571","article-title":"Pharmacogenomics of Aromatase Inhibitors in Postmenopausal Breast Cancer and Additional Mechanisms of Anastrozole Action","volume":"5","author":"Cairns","year":"2020","journal-title":"JCI Insight"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","article-title":"Aromatase Inhibitors versus Tamoxifen in Early Breast Cancer: Patient-Level Meta-Analysis of the Randomised Trials","volume":"386","author":"Bradley","year":"2015","journal-title":"Lancet"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/JCO.18.00440","article-title":"Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women with Hormone Receptor\u2013Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial","volume":"37","author":"Ruhstaller","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/S1470-2045(21)00758-0","article-title":"Aromatase Inhibitors versus Tamoxifen in Premenopausal Women with Oestrogen Receptor-Positive Early-Stage Breast Cancer Treated with Ovarian Suppression: A Patient-Level Meta-Analysis of 7030 Women from Four Randomised Trials","volume":"23","author":"Bradley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s12032-022-01749-1","article-title":"Molecular Perspective on Targeted Therapy in Breast Cancer: A Review of Current Status","volume":"39","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Ligasov\u00e1, A., Frydrych, I., and Koberna, K. (2023). Basic Methods of Cell Cycle Analysis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043674"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Sun, Y., Liu, Y., Ma, X., and Hu, H. (2021). The Influence of Cell Cycle Regulation on Chemotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136923"},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Purohit, L., Jones, C., Gonzalez, T., Castrellon, A., and Hussein, A. (2024). The Role of CD4\/6 Inhibitors in Breast Cancer Treatment. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25021242"},{"key":"ref_197","doi-asserted-by":"crossref","unstructured":"Piezzo, M., Cocco, S., Caputo, R., Cianniello, D., Di Gioia, G., Di Lauro, V., Fusco, G., Martinelli, C., Nuzzo, F., and Pensabene, M. (2020). Targeting Cell Cycle in Breast Cancer: CDK4\/6 Inhibitors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186479"},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/MTOR Signaling Pathway for Targeted Therapeutic Treatment in Human Cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Alves, C.L., and Ditzel, H.J. (2023). Drugging the PI3K\/AKT\/MTOR Pathway in ER+ Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24054522"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","article-title":"Targeting PI3K Family with Small-Molecule Inhibitors in Cancer Therapy: Current Clinical Status and Future Directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/annonc\/mdz381","article-title":"Efficacy of PI3K Inhibitors in Advanced Breast Cancer","volume":"30","author":"Verret","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1007\/s40265-020-01394-w","article-title":"Targeting the PI3K\/AKT\/MTOR Pathway in Hormone Positive Breast Cancer","volume":"80","author":"Nunnery","year":"2020","journal-title":"Drugs"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","article-title":"PI3K Inhibitors in Breast Cancer Therapy","volume":"21","author":"Ellis","year":"2019","journal-title":"Curr. Oncol. Rep."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.bbcan.2018.08.001","article-title":"The next Generation of PI3K-Akt-MTOR Pathway Inhibitors in Breast Cancer Cohorts","volume":"1870","author":"Kenna","year":"2018","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","article-title":"PI3K\/AKT\/MTOR Signaling Pathway: An Important Driver and Therapeutic Target in Triple-Negative Breast Cancer","volume":"31","author":"Zhang","year":"2024","journal-title":"Breast Cancer"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.str.2023.01.007","article-title":"ATP-Competitive and Allosteric Inhibitors Induce Differential Conformational Changes at the Autoinhibitory Interface of Akt1","volume":"31","author":"Shaw","year":"2023","journal-title":"Structure"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in Hormone Receptor\u2013Positive Advanced Breast Cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1158\/1078-0432.CCR-20-2114","article-title":"Phase I\/II Trial of Triplet Therapy (Exemestane, Ribociclib, and Everolimus) after Progression on a CDK4\/6 Inhibitor in HR+\/HER2\u2212 Advanced Breast Cancer (TRINITI-1)","volume":"27","author":"Bardia","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s10147-024-02528-w","article-title":"Relationship between HER2-Low Status and Efficacy of CDK4\/6 Inhibitors in Advanced Breast Cancer: A Real-World Study","volume":"29","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"e13034","DOI":"10.1200\/JCO.2024.42.16_suppl.e13034","article-title":"Effect of HER2-Low Expression on the Efficacy of CDK4\/6 Inhibitors in Breast Cancer: A Meta-Analysis","volume":"42","author":"Ye","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41523-023-00534-1","article-title":"Prognostic Significance of HER2-Low Status in HR-Positive\/HER2-Negative Advanced Breast Cancer Treated with CDK4\/6 Inhibitors","volume":"9","author":"Zattarin","year":"2023","journal-title":"npj Breast Cancer"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2024-12-1","DOI":"10.7573\/dic.2024-12-1","article-title":"Patterns of Treatment and Outcomes of Patients with Metastatic HER2-Low Breast Cancer Treated with CDK4\/6 Inhibitors and Hormone Therapy","volume":"14","author":"Sottotetti","year":"2025","journal-title":"Drugs Context"},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Kim, E.H., Ryu, Y., Choi, J., Park, D., Lee, J.W., Chi, S.G., Kim, S.H., and Yang, Y. (2024). Targeting MiR-21 to Overcome P-Glycoprotein Drug Efflux in Doxorubicin-Resistant 4T1 Breast Cancer. Biomater. Res., 28.","DOI":"10.34133\/bmr.0095"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"102193","DOI":"10.1016\/j.omtn.2024.102193","article-title":"Selective Targeting of Chemically Modified MiR-34a to Prostate Cancer Using a Small Molecule Ligand and an Endosomal Escape Agent","volume":"35","author":"Abdelaal","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.21037\/tlcr-21-299","article-title":"Let-7b-3p Inhibits Tumor Growth and Metastasis by Targeting the BRF2-Mediated MAPK\/ERK Pathway in Human Lung Adenocarcinoma","volume":"10","author":"Li","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Pan, W., Tan, Y., Chen, X., Zeng, L., Lv, Y., and Yang, J. (2025). MiRNA-204-5p Acts as a Tumor Suppressor in Gastric Cancer by Inhibiting Cell Migration, Invasion, and Glycolysis via the RAB22A\/PI3K\/AKT Axis. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-02139-z"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13046-020-01649-0","article-title":"MicroRNA-148a-3p Inhibits Progression of Hepatocelluar Carcimoma by Repressing SMAD2 Expression in an Ago2 Dependent Manner","volume":"39","author":"Huang","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Ho, P.T.B., Clark, I.M., and Le, L.T.T. (2022). MicroRNA-Based Diagnosis and Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23137167"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"33","DOI":"10.21037\/pcm-21-28","article-title":"A Narrative Review of MicroRNA Therapeutics: Understanding the Future of MicroRNA Research","volume":"4","author":"Liang","year":"2021","journal-title":"Precis. Cancer Med."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17460441.2020.1765770","article-title":"Challenges Identifying Efficacious MiRNA Therapeutics for Cancer","volume":"15","author":"Segal","year":"2020","journal-title":"Expert. Opin. Drug Discov."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2014.10.031","article-title":"Recent Progress in MicroRNA Delivery for Cancer Therapy by Non-Viral Synthetic Vectors","volume":"81","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In Vivo Delivery of MiRNAs for Cancer Therapy: Challenges and Strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_223","doi-asserted-by":"crossref","unstructured":"Chaudhary, V., Jangra, S., and Yadav, N.R. (2018). Nanotechnology Based Approaches for Detection and Delivery of MicroRNA in Healthcare and Crop Protection. J. Nanobiotechnol., 16.","DOI":"10.1186\/s12951-018-0368-8"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-014-0086-0","article-title":"Circulating MiRNAs in Cancer: From Detection to Therapy","volume":"7","author":"Wang","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Dasgupta, I., and Chatterjee, A. (2021). Recent Advances in MiRNA Delivery Systems. Methods Protoc., 4.","DOI":"10.3390\/mps4010010"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.3892\/or.2020.7791","article-title":"Lipid-Based Nanoparticles for the Therapeutic Delivery of Non-Coding RNAs in Breast Cancer","volume":"44","year":"2020","journal-title":"Oncol. Rep."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"8641","DOI":"10.2147\/IJN.S471900","article-title":"Delivery of MiRNAs Using Nanoparticles for the Treatment of Osteosarcoma","volume":"19","author":"Wang","year":"2024","journal-title":"Int. J. Nanomed."},{"key":"ref_228","doi-asserted-by":"crossref","unstructured":"Moraes, F.C., Pichon, C., Letourneur, D., and Chaubet, F. (2021). MiRNA Delivery by Nanosystems: State of the Art and Perspectives. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13111901"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.msec.2018.07.027","article-title":"Polyester-Based Nanoparticles for Nucleic Acid Delivery","volume":"92","author":"Zhao","year":"2018","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.2217\/nnm-2016-0128","article-title":"New Polymer of Lactic-Co-Glycolic Acid-Modified Polyethylenimine for Nucleic Acid Delivery","volume":"11","author":"Liang","year":"2016","journal-title":"Nanomedicine"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.apsb.2020.10.005","article-title":"Small Interfering RNA for Cancer Treatment: Overcoming Hurdles in Delivery","volume":"10","author":"Charbe","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"119489","DOI":"10.1016\/j.carbpol.2022.119489","article-title":"Chitosan Nanocarriers for MicroRNA Delivery and Detection: A Preliminary Review with Emphasis on Cancer","volume":"290","author":"Sargazi","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-1-4939-7138-1_14","article-title":"Chitosan Nanoparticles for MiRNA Delivery","volume":"1632","author":"Denizli","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41392-024-01735-1","article-title":"Extracellular Vesicles as Tools and Targets in Therapy for Diseases","volume":"9","author":"Kumar","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1016\/j.ymthe.2024.02.025","article-title":"Therapeutic Potential of RNA-Enriched Extracellular Vesicles: The next Generation in RNA Delivery via Biogenic Nanoparticles","volume":"32","author":"Muskan","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_236","doi-asserted-by":"crossref","unstructured":"Picon, M.A., Wang, L., Da Fonseca Ferreira, A., Dong, C., and Marzouka, G.R. (2023). Extracellular Vesicles as Delivery Systems in Disease Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242417134"},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 Study of MRX34, a Liposomal MiR-34a Mimic, in Patients with Advanced Solid Tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and Activity of MicroRNA-Loaded Minicells in Patients with Recurrent Malignant Pleural Mesothelioma: A First-in-Man, Phase 1, Open-Label, Dose-Escalation Study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"422","DOI":"10.18632\/oncotarget.27894","article-title":"Multi-Modal Effects of 1B3, a Novel Synthetic MiR-193a-3p Mimic, Support Strong Potential for Therapeutic Intervention in Oncology","volume":"12","author":"Telford","year":"2021","journal-title":"Oncotarget"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18632\/oncotarget.28608","article-title":"INT-1B3, an LNP Formulated MiR-193a-3p Mimic, Promotes Anti-Tumor Immunity by Enhancing T Cell Mediated Immune Responses via Modulation of the Tumor Microenvironment and Induction of Immunogenic Cell Death","volume":"15","author":"Duurland","year":"2024","journal-title":"Oncotarget"},{"key":"ref_241","unstructured":"ClinicalTrials.gov First-in-Human Study of INT-1B3 in Patients with Advanced Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04675996."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Ouyang, B., Bi, M., Jadhao, M., Bick, G., and Zhang, X. (2024). MiR-205 Regulates Tamoxifen Resistance by Targeting Estrogen Receptor Coactivator MED1 in Human Breast Cancer. Cancers, 16.","DOI":"10.3390\/cancers16233992"},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13046-019-1039-9","article-title":"MiR-190 Enhances Endocrine Therapy Sensitivity by Regulating SOX9 Expression in Breast Cancer","volume":"38","author":"Yu","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Ghanbari, M., Karari, K., Altalebi, S.A.R., Majeed, S.A., and Haghi, M. (2025). The Role of MicroRNAs in Breast Cancer: Diagnostic and Therapeutic Implications. Int. J. Biol. Macromol., 321.","DOI":"10.1016\/j.ijbiomac.2025.146386"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1007\/s00210-024-03770-9","article-title":"Investigation of Circulating MiR-182-3p, MiR -382-3p and MiR-93, MiR-142-3p Involved in Tamoxifen Resistance and Sensitivity in Luminal-Subtype Breast Cancer Patients: A Case\u2013Control Study","volume":"398","author":"Sanaat","year":"2025","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"7600","DOI":"10.1111\/jcmm.15396","article-title":"MiR-126 Reduces Trastuzumab Resistance by Targeting PIK3R2 and Regulating AKT\/MTOR Pathway in Breast Cancer Cells","volume":"24","author":"Fu","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"19127","DOI":"10.1074\/jbc.M110.216887","article-title":"Up-Regulation of MiR-21 Mediates Resistance to Trastuzumab Therapy for Breast Cancer","volume":"286","author":"Gong","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1111\/jcmm.14681","article-title":"MiR-200c Suppresses Stemness and Increases Cellular Sensitivity to Trastuzumab in HER2+ Breast Cancer","volume":"23","author":"Tang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Fogazzi, V., Kapahnke, M., Cataldo, A., Plantamura, I., Tagliabue, E., Di Cosimo, S., Cosentino, G., and Iorio, M.V. (2022). The Role of MicroRNAs in HER2-Positive Breast Cancer: Where We Are and Future Prospective. Cancers, 14.","DOI":"10.3390\/cancers14215326"},{"key":"ref_250","doi-asserted-by":"crossref","unstructured":"Tormo, E., Adam-Artigues, A., Ballester, S., Pineda, B., Zazo, S., Gonz\u00e1lez-Alonso, P., Albanell, J., Rovira, A., Rojo, F., and Lluch, A. (2017). The Role of MiR-26a and MiR-30b in HER2+ Breast Cancer Trastuzumab Resistance and Regulation of the CCNE2 Gene. Sci. Rep., 7.","DOI":"10.1038\/srep41309"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"18295","DOI":"10.18632\/oncotarget.7577","article-title":"A Novel Double-Negative Feedback Loop between MiR-489 and the HER2-SHP2-MAPK Signaling Axis Regulates Breast Cancer Cell Proliferation and Tumor Growth","volume":"7","author":"Patel","year":"2016","journal-title":"Oncotarget"},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"6189","DOI":"10.1038\/onc.2016.151","article-title":"MiR-16 Mediates Trastuzumab and Lapatinib Response in ErbB-2-Positive Breast and Gastric Cancer via Its Novel Targets CCNJ and FUBP1","volume":"35","author":"Venturutti","year":"2016","journal-title":"Oncogene"},{"key":"ref_253","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Yuan, Y., Li, L., Wang, X., Quan, Y., Liu, C., Yu, M., Hu, X., Meng, X., and Zhou, Z. (2021). HER2-Intronic MiR-4728-5p Facilitates HER2 Expression and Accelerates Cell Proliferation and Migration by Targeting EBP1 in Breast Cancer. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0245832"},{"key":"ref_254","doi-asserted-by":"crossref","unstructured":"Newie, I., S\u00f8kilde, R., Persson, H., Grabau, D., Rego, N., Kvist, A., Von Stedingk, K., Axelson, H., Borg, \u00c5., and Vallon-Christersson, J. (2014). The HER2-Encoded MiR-4728-3p Regulates ESR1 through a Non-Canonical Internal Seed Interaction. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097200"},{"key":"ref_255","doi-asserted-by":"crossref","unstructured":"Mutlu, M., Saatci, \u00d6., Ansari, S.A., Yurdusev, E., Shehwana, H., Konu, \u00d6., Raza, U., and \u015eahin, \u00d6. (2016). MiR-564 Acts as a Dual Inhibitor of PI3K and MAPK Signaling Networks and Inhibits Proliferation and Invasion in Breast Cancer. Sci. Rep., 6.","DOI":"10.1038\/srep32541"},{"key":"ref_256","doi-asserted-by":"crossref","unstructured":"Zhang, X., Li, Y., Wang, D., and Wei, X. (2017). MiR-22 Suppresses Tumorigenesis and Improves Radiosensitivity of Breast Cancer Cells by Targeting Sirt1. Biol. Res., 50.","DOI":"10.1186\/s40659-017-0133-8"},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"Normann, L.S., Aure, M.R., Leivonen, S.K., Haugen, M.H., Hongisto, V., Kristensen, V.N., M\u00e6landsmo, G.M., and Sahlberg, K.K. (2021). MicroRNA in Combination with HER2-Targeting Drugs Reduces Breast Cancer Cell Viability in Vitro. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90385-2"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/dna.2018.4427","article-title":"Involvement of the Dysregulation of MiR-23b-3p, MiR-195-5p, MiR-656-5p, and MiR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance","volume":"38","author":"Rezaei","year":"2019","journal-title":"DNA Cell Biol."},{"key":"ref_259","doi-asserted-by":"crossref","unstructured":"Chen, L., Ye, L., Liang, Y., Luo, W., Zuo, Q., Huang, P., Hu, Y., Dai, Y., Wu, Y., and Guo, Q. (2024). Neratinib Enhances the Efficacy of CDK4\/6 Inhibitor plus Endocrine Therapy in HR+\/HER2-Low Breast Cancer Cell Line ZR-75-1 via Hsa-MiR-23a-5p. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-82137-9"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T05:17:25Z","timestamp":1763529445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/22\/3672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":259,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["cancers17223672"],"URL":"https:\/\/doi.org\/10.3390\/cancers17223672","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]}}}